// App-Quantinova.ai

: Glofitamab Monotherapy Induces High Complete Response Rates in Patients with Heavily Pretreated Relapsed or Refractory Mantle Cell Lymphoma

Researchers

Presenter

  • Tycel J. Phillips

Principal Investigators

  • Michael Dickinson

  • Franck Morschhauser

  • Emmanuel Bachy

  • Michael Crump

  • Marek Trneny

  • Nancy L. Bartlett

  • Jan Zaucha

  • Tomasz Wrobel

  • Fritz Offner

  • Kathryn Humphrey

  • Linda Lundberg

  • James Relf

  • Audrey Filézac de L'Étang

  • David Carlile

  • Ben Byrne

  • Naseer Qayum

  • Carmelo Carlo-Stella

Medical Centers

  • University of Michigan Medical School, Ann Arbor, MI

  • Peter MacCallum Cancer Centre, Royal Melbourne Hospital and The University of Melbourne, Melbourne, Australia

  • Siteman Cancer Center, Washington University, St. Louis, MO

  • Dept Hematology Universitair Ziekenhuis, Gent, Belgium

  • Hematology Department, Lille University Hospital, Lille, France

  • Princess Margaret Hospital, Toronto, Canada

  • Hospices Civils De Lyon and Université Claude Bernard, Pierre-Bénite, France

  • st Fac Medicine, Charles University, General Hospital, Prague, Czech Republic

  • Medical University of Gdansk, Gdansk, Poland

  • Humanitas University and IRCCS Humanitas Research Hospital, Milan, Italy

  • Wroclaw Medical University, Wroclaw, Poland

Locations

  • United States

  • Belgium

  • France

  • United Kingdom

  • Italy

  • Australia

  • Czech Republic

  • Switzerland

  • Poland

  • Canada

Companies

  • Feng Chi Biotech Cor

  • F. Hoffmann-La Roche

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Mantle cell lymphoma

Biomarkers

  • N/A

Drug/Treatment

  • Obinutuzumab

  • Obinutuzumab Intravenous

  • Ibrutinib

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I/II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved